Welcome to our dedicated page for Allarity SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allarity Therapeutics, Inc. SEC filings document the company’s clinical-stage oncology business, capital structure, governance, and material-event disclosures. The filings identify Allarity’s Nasdaq-listed common stock and emerging growth company status, and include 8-K reports covering Regulation FD presentations, scientific and clinical updates for stenoparib and the DRP® companion diagnostic, intellectual-property developments, operating and financial results, and promissory-note financing.
Proxy materials describe annual meeting matters and stockholder voting procedures, while material definitive agreement filings and other current reports provide formal disclosure on financing arrangements, corporate progress, and regulatory or clinical communications tied to Allarity’s precision oncology programs.
Allarity Therapeutics, Inc. filed an S-3 shelf registration describing an offering that includes 760,916 shares of Common Stock and 801,584 Pre-Funded Warrants exercisable for Common Stock at an exercise price of $0.0001 per share. The company’s authorized capital structure includes 250,000,000 shares of Common Stock and 500,000 shares of undesignated preferred stock. The prospectus enumerates the distribution methods permitted under the plan, including ordinary brokerage transactions, block trades, principal purchases and exchange distributions. The document lists estimated offering expenses including $20,000 for accounting fees and $50,000 for legal fees. A table of exhibits identifies corporate charter amendments, bylaws, a specimen stock certificate, forms of pre-funded warrant, a securities purchase agreement and a registration rights agreement dated September 22, 2025. The filing is signed by the CEO, CFO and multiple directors with signatures dated September 25, 2025.
Allarity Therapeutics, Inc. reported that Dr. Jeremy Graff, its President and Chief Development Officer, presented new and updated clinical data from the company’s ongoing Phase 2 trial in advanced ovarian cancer. The presentation took place at the American Association for Cancer Research 7th Biennial Special Conference on Ovarian Cancer, held September 19–21, 2025, at the Grand Hyatt Denver in Denver, Colorado.
The company also noted that a press release dated September 22, 2025, containing further details on the Phase 2 trial update has been issued and is included as an exhibit.
Allarity Therapeutics, Inc. reported that Dr. Jeremy Graff, its President and Chief Development Officer, presented new and updated clinical data from the company’s ongoing Phase 2 trial in advanced ovarian cancer. The presentation took place at the American Association for Cancer Research 7th Biennial Special Conference on Ovarian Cancer, held September 19–21, 2025, at the Grand Hyatt Denver in Denver, Colorado.
The company also noted that a press release dated September 22, 2025, containing further details on the Phase 2 trial update has been issued and is included as an exhibit.
Allarity Therapeutics, Inc. filed a Form 8-K reporting a material event dated September 22, 2025. The filing lists two material agreements as exhibits: a Form of Securities Purchase Agreement and a Form of Registration Rights Agreement, each dated September 22, 2025, described as between the company and an investor. The document identifies the company's common stock ticker as ALLR on The Nasdaq Stock Market LLC and is signed by Thomas H. Jensen, Chief Executive Officer. The filing includes an Inline XBRL cover page reference but does not disclose financial terms, investor identity, or the size or economic impact of the transaction.
Allarity Therapeutics, Inc. filed a Form 8-K reporting a material event dated September 22, 2025. The filing lists two material agreements as exhibits: a Form of Securities Purchase Agreement and a Form of Registration Rights Agreement, each dated September 22, 2025, described as between the company and an investor. The document identifies the company's common stock ticker as ALLR on The Nasdaq Stock Market LLC and is signed by Thomas H. Jensen, Chief Executive Officer. The filing includes an Inline XBRL cover page reference but does not disclose financial terms, investor identity, or the size or economic impact of the transaction.
Allarity Therapeutics, Inc. reported that its CEO, Thomas Jensen, has been invited to present at the Biomarkers & Precision Medicine 2025 conference in London, organized by Oxford Global. The company also furnished a related press release as an exhibit, providing additional details on this conference participation.
Allarity Therapeutics, Inc. reported that its CEO, Thomas Jensen, has been invited to present at the Biomarkers & Precision Medicine 2025 conference in London, organized by Oxford Global. The company also furnished a related press release as an exhibit, providing additional details on this conference participation.
Allarity Therapeutics, Inc. reported that the U.S. Food and Drug Administration has granted Fast Track designation to stenoparib, its investigational treatment for patients with advanced ovarian cancer. The company disclosed that this development was announced in a press release dated August 26, 2025, which is included as an exhibit to the report.
Allarity Therapeutics, Inc. reported interim results showing constrained operations but sufficient near-term liquidity. The company recorded a net loss of $5.1 million for the six months ended June 30, 2025 and negative operating cash flow of $8.2 million over the same period. Management states that $17.8 million of cash, cash equivalents and restricted cash as of June 30, 2025 is estimated to be sufficient to fund operations for at least the next 12 months under the current plan. The company completed corporate actions including Reverse Stock Splits (retroactively applied) and repurchased 2,455,702 shares for $2,565,511, leaving $2,434,489 available under its repurchase program. A legal/contract liability to Novartis resulted in current liabilities recorded as $3.6 million accounts payable, $1.4 million convertible promissory notes and accrued interest, and $0.4 million accrued liabilities. The company settled a prior SEC investigation by paying a $2.5 million civil penalty which was paid in cash on April 2, 2025.
Allarity Therapeutics, Inc. filed a notice that its Quarterly Report on Form 10-Q for the period ended June 30, 2025 will be filed late. The company says its financial statements for the quarter are still being reviewed by its certifying auditors and that this review must be completed before the report can be finalized.
Management states that filing the Form 10-Q and related XBRL exhibit by the original deadline would require unreasonable effort or expense, but it reasonably believes the report will be completed and filed within the allowed five-day extension period.
On 15 Jul 2025 Allarity Therapeutics, Inc. (NASDAQ: ALLR) filed a Form 8-K under Item 8.01 to disclose the execution of a new commercial agreement with an undisclosed EU-based biotechnology company. The filing states only that the agreement was announced via a press release furnished as Exhibit 99.1, which is incorporated by reference.
No financial terms, partner identity, milestones, or projected revenue were provided in the 8-K, and the company did not report any changes to financial statements, guidance, or capital structure. Other 8-K items were not triggered. Investors must review Exhibit 99.1 for substantive economic details before assessing materiality.